白细胞介素-2在肾细胞癌中的应用：已是明日黄花还是仍具可行性？
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?
作者信息
Amin Asim, White Richard L
机构信息
Divisions of Immunotherapy and Medical Oncology, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina, USA; Divisions of Surgical Oncology and Immunotherapy, Levine Cancer Institute, Carolinas Medical Center, Charlotte, North Carolina, USA.
出版信息
J Kidney Cancer VHL. 2014 Nov 23;1(7):74-83. doi: 10.15586/jkcvhl.2014.18. eCollection 2014.
Abstract
Modulation of the immune response plays an important role in the natural history of renal cell carcinoma. Spontaneous regression of metastases has been well documented in a small percentage of patients after they undergo de-bulking nephrectomy without any additional systemic intervention. The only logical explanation for these observations is "resetting" of the balance between tumor and the host immune system that, having been overwhelmed by the tumor burden, is able to function better after tumor de-bulking. Attempts to modulate the activity of the immune system "on demand" have included the use of vaccines, cytokines/lymphokines, adoptive cell transfer, monoclonal antibodies and most recently manipulation of immune checkpoint inhibitors. Here we review the data for infusional interleukin-2 in the management of advanced renal cell carcinoma and its role in current clinical practice.
摘要
免疫反应的调节在肾细胞癌的自然病程中起着重要作用。在一小部分患者接受减瘤性肾切除术后，未经任何额外的全身干预，转移灶出现自发消退，这一点已有充分记录。对这些观察结果唯一合理的解释是肿瘤与宿主免疫系统之间的平衡“重置”，免疫系统在被肿瘤负荷压倒后，在肿瘤减瘤后能够更好地发挥作用。“按需”调节免疫系统活性的尝试包括使用疫苗、细胞因子/淋巴因子、过继性细胞转移、单克隆抗体，以及最近对免疫检查点抑制剂的操控。在此，我们回顾了输注白细胞介素-2在晚期肾细胞癌治疗中的数据及其在当前临床实践中的作用。
相似文献
1
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?白细胞介素-2在肾细胞癌中的应用：已是明日黄花还是仍具可行性？
J Kidney Cancer VHL. 2014 Nov 23;1(7):74-83. doi: 10.15586/jkcvhl.2014.18. eCollection 2014.
2
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.免疫检查点抑制剂或靶向治疗的转移性肾细胞癌患者的 upfront 减瘤性肾切除术：来自国际转移性肾细胞癌数据库联盟的一项观察性研究
Eur Urol. 2023 Feb;83(2):145-151. doi: 10.1016/j.eururo.2022.10.004. Epub 2022 Oct 20.
3
Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.多原发恶性肿瘤患者对免疫检查点抑制剂（ICI）治疗的不同反应：机器人辅助部分肾切除术（RP）后出现的 PD-L1 阴性输尿管和肺转移的透明细胞肾细胞癌，对 ICI 治疗后进展，而同步 PD-L1 阳性原发性肺鳞癌对 ICI 治疗反应良好：病例报告。
World J Surg Oncol. 2023 Feb 6;21(1):37. doi: 10.1186/s12957-023-02920-2.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Spontaneous regression of multiple pulmonary metastases accompanied by normalization of serum immune markers following cytoreductive nephrectomy in a patient with clear-cell renal cell carcinoma.一名透明细胞肾细胞癌患者在进行减瘤性肾切除术后，肺部多处转移灶出现自发消退，同时血清免疫标志物恢复正常。
IJU Case Rep. 2020 Dec 26;4(2):95-99. doi: 10.1002/iju5.12252. eCollection 2021 Mar.
6
Bladder metastasis with additional metastases in multiple other organs 4 years after radical nephrectomy for clear cell renal cell carcinoma: a case report and review of the literature.根治性肾切除术后 4 年发生膀胱转移伴多个其他器官转移的 clear cell 肾细胞癌：病例报告及文献复习。
J Med Case Rep. 2022 Apr 3;16(1):131. doi: 10.1186/s13256-022-03368-w.
7
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.联合免疫治疗时代接受延迟性、先行性或不进行减瘤性肾切除术的转移性肾细胞癌患者的特征：国际转移性肾细胞癌数据库联盟的结果
Eur Urol Oncol. 2024 Jun;7(3):501-508. doi: 10.1016/j.euo.2023.10.002. Epub 2023 Oct 31.
8
Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation.经免疫检查点抑制剂初始治疗后肾细胞癌合并肺癌性淋巴管炎完全缓解，随后行部分肾切除术进行手术巩固治疗。
IJU Case Rep. 2022 Mar 25;5(3):168-171. doi: 10.1002/iju5.12427. eCollection 2022 May.
9
Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.接受肿瘤浸润淋巴细胞和白细胞介素-2 疗法的转移性肾细胞癌患者的自然免疫反应相关治疗反应
J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):149-61. doi: 10.1097/00002371-199603000-00008.
10
Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.免疫检查点抑制剂治疗转移性肾细胞癌后的根治性肾切除术。
Eur Urol Focus. 2023 Mar;9(2):275-277. doi: 10.1016/j.euf.2023.01.022. Epub 2023 Feb 10.
引用本文的文献
1
Refined control of CRISPR-Cas9 gene editing in : the creation of recombinant strains for therapeutic applications.精细控制 CRISPR-Cas9 基因编辑：用于治疗应用的重组菌株的创建。
Front Immunol. 2023 Oct 5;14:1241632. doi: 10.3389/fimmu.2023.1241632. eCollection 2023.
2
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition.基于单域抗体的强效双特异性 IL-18 模拟物的产生和工程改造，可抵抗 IL-18BP 诱饵受体抑制。
MAbs. 2023 Jan-Dec;15(1):2236265. doi: 10.1080/19420862.2023.2236265.
3
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.免疫检查点抑制剂和 IL2 反应的预测性免疫基因组特征：晚期肾癌患者的真实世界证据研究。
Cancer Res Commun. 2022 Aug 30;2(8):894-903. doi: 10.1158/2767-9764.CRC-21-0153. eCollection 2022 Aug.
4
Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress.免疫调节细胞因子疗法的工程策略——挑战与临床进展
Adv Ther (Weinh). 2021 Aug;4(8). doi: 10.1002/adtp.202100035. Epub 2021 Apr 2.
5
Efficient Secretion of Murine IL-2 From an Attenuated Strain of , a Novel Delivery Vehicle for Cancer Immunotherapy.来自减毒株的小鼠白细胞介素-2的高效分泌，一种用于癌症免疫治疗的新型递送载体。
Front Microbiol. 2021 Jun 8;12:669488. doi: 10.3389/fmicb.2021.669488. eCollection 2021.
6
Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.溶瘤痘苗病毒基因修饰及其细胞因子表达对肿瘤感染、免疫反应和杀伤的影响。
Mol Cancer Ther. 2021 Aug;20(8):1481-1494. doi: 10.1158/1535-7163.MCT-20-0863. Epub 2021 May 27.
7
Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy.接受免疫治疗的终末期癌症患者的细胞因子分析
Vaccines (Basel). 2021 Mar 8;9(3):235. doi: 10.3390/vaccines9030235.
8
Quantifying the limits of CAR T-cell delivery in mice and men.量化 CAR T 细胞在小鼠和人体内的递送极限。
J R Soc Interface. 2021 Mar;18(176):20201013. doi: 10.1098/rsif.2020.1013. Epub 2021 Mar 3.
9
Sarcomatoid renal cell carcinoma: biology, natural history and management.肉瘤样肾细胞癌：生物学、自然史与治疗。
Nat Rev Urol. 2020 Dec;17(12):659-678. doi: 10.1038/s41585-020-00382-9. Epub 2020 Oct 13.
10
A Microdosing Study with Tc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients.Tc-PHC-102 微剂量研究用于肾细胞癌患者原发和转移病灶的 SPECT/CT 成像。
J Nucl Med. 2021 Mar;62(3):360-365. doi: 10.2967/jnumed.120.245530. Epub 2020 Jul 17.
本文引用的文献
1
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.纳武单抗联合伊匹木单抗治疗转移性肾细胞癌的安全性和疗效：CheckMate 016研究
J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.
2
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).利用登记处改善癌症治疗：接受白细胞介素-2 (IL-2) 治疗的患者的国家数据库。
J Pers Med. 2014 Mar 7;4(1):52-64. doi: 10.3390/jpm4010052.
3
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.纳武单抗治疗转移性肾细胞癌：一项随机II期试验的结果
J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.
4
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program.社区医院生物治疗计划中高剂量白细胞介素-2 治疗黑色素瘤和肾癌的持久反应和可逆毒性。
J Immunother Cancer. 2014 May 14;2:13. doi: 10.1186/2051-1426-2-13. eCollection 2014.
5
High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience.大剂量白细胞介素-2 治疗转移性肾细胞癌：当代经验。
Urology. 2014 May;83(5):1129-34. doi: 10.1016/j.urology.2014.02.005.
6
High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?高剂量白细胞介素-2：在靶向治疗时代，它对黑色素瘤和肾细胞癌还适用吗？
Oncology (Williston Park). 2013 Jul;27(7):680-91.
7
The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.
8
Cancer immunotherapy comes of age.癌症免疫疗法走向成熟。
J Clin Oncol. 2011 Dec 20;29(36):4828-36. doi: 10.1200/JCO.2011.38.0899. Epub 2011 Oct 31.
9
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.接受血管内皮生长因子靶向药物治疗的转移性肾细胞癌患者总生存的预后因素：一项大型多中心研究的结果
J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13.
10
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.既往接受VEGF靶向治疗的晚期肾细胞癌患者使用白细胞介素-2的安全性和疗效的回顾性分析。
J Immunother. 2009 Feb-Mar;32(2):181-5. doi: 10.1097/CJI.0b013e3181952b1d.
Zotero 插件